We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $109.09 as of Nov 11th. NVO’s trailing and forward P/E were 35.82 and 27.70 respectively according to Yahoo Finance.
A closeup of pills in a pharmacy, representing the high quality medications of the company.
Novo Nordisk (NVO) is offering a unique opportunity for investors who may have missed out during its earlier surge, with the stock now priced attractively. This second chance is supported by both technical and fundamental indicators. NVO’s relative strength index (RSI) near 30 signals an oversold condition, positioning the stock for a likely rebound as we approach the traditionally strong year-end season.
Fundamentally, NVO’s fair value estimate (FVE) remains solid at DKK870, with no need for adjustments despite some minor deviations in operating profits. Revenue projections for 2025 indicate growth around 21%, aligning with recent comments by CFO Karsten Munk Knudsen, who foresees sales growth in the high teens. This tempered forecast, coupled with high capital expenditures, briefly pressured the stock down by 3-4%. However, minor fluctuations in revenue growth don’t overshadow NVO’s strong profit margins and strategic investments, which continue to support its fair valuation.
NVO’s leading market position in diabetes and obesity remains unthreatened, with a 33% share that shows no signs of decline. Competitors have struggled to penetrate NVO’s dominance in these segments, where it remains highly specialized and committed to innovation. The stock’s price has slightly pulled back, partly due to competitive pricing dynamics linked to increased patient subscriptions for its weight-loss treatments, Wegovy and Zepbound. This shift reflects a more realistic pricing environment but does not diminish the overall market potential for obesity treatments.
Driving NVO’s wide moat is a robust innovation pipeline featuring therapies like CagriSema and oral semaglutide formulations. CagriSema, a combination of semaglutide and cagrilintide, is moving into Phase 3 trials and has shown promising early results in weight reduction. Oral semaglutide, part of the OASIS trial program, is exploring treatment for obesity and could expand to dual receptor targets, enhancing NVO’s reach in diabetes and weight management. The SOUL, FOCUS, and STRIDE programs further diversify NVO’s pipeline, addressing multiple comorbidities like cardiovascular and kidney diseases alongside diabetes and obesity.
With its strong R&D pipeline and dominant position in key treatment areas, NVO remains an attractive investment at current levels. While smaller players struggle to keep pace, NVO’s consistent innovation solidifies its market leadership, making it a compelling buy with long-term growth potential.
Novo Nordisk A/S (NVO) is also not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 67 hedge fund portfolios held NVO at the end of the second quarter which was 60 in the previous quarter. While we acknowledge the risk and potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.